Multinational pharmaceutical company Q3 report card: Pfizer Merck leads the growth rate, and the prospects of each company's TOP3 competitive products are different

Entering the third quarter of 2021 financial reporting season, major multinational pharmaceutical giants have released their latest quarterly reports
.

As of today, in addition to AstraZeneca, other large pharmaceutical companies include Pfizer, Johnson & Johnson, Roche, AbbVie, Merck, Novartis, GSK, Sanofi, Bristol-Myers Squibb and Amgen.

Due to the continuing impact of the epidemic, sales staff of many pharmaceutical manufacturers have reduced the opportunity to enter clinics for face-to-face sales with doctors.
Many patients have reduced the frequency of visiting clinics and supplementing medicines due to declining income or fear of viral infections
.

Various reasons have had varying degrees of negative impact on the sales of many drugs, especially new drugs that were on the market during the epidemic

Revenues and trends of multinational pharmaceutical companies in the third quarter of 2021 (unit: 100 million US dollars)

Revenues and trends of multinational pharmaceutical companies in the third quarter of 2021 (unit: 100 million US dollars)

Note:

1.
The ranking is based on the total revenue in the third quarter of 2021, from high to low

2.
As AstraZeneca's third-quarter financial report will be released in mid-November, the data has not yet been disclosed

3.
Pfizer’s total revenue in the third quarter includes Comirnaty (new crown vaccine, revenue of $13 billion in the third quarter); if you exclude this vaccine revenue, Pfizer’s revenue in the third quarter is $11.
1 billion, an increase of 7%

4.
GSK's total revenue includes vaccines and consumer health income

5.
The growth rate calculation excludes the impact of exchange rates

0 1.
Pfizer's new crown vaccine shows its prowess andMerck may be approved the first oral new crown treatment drug

0 1.
Pfizer's new crown vaccine shows its prowess andMerck may be approved the first oral new crown treatment drug

In the third quarter, in terms of revenue growth rate, multinational pharmaceutical companies all delivered good answers
.

Among them, Pfizer and Merck & Co.

Pfizer:

Pfizer:

Pfizer and BioNTech successfully cooperated in the development of a vaccine to combat the new crown epidemic.
Its global sales of vaccines in the third quarter exceeded $13 billion , which also helped Pfizer achieve an astonishing 130% year-on-year growth in the third quarter of 2021
.

Even excluding vaccine revenue, Pfizer's revenue increased by 7% from the same period last year

The global sales of its vaccines in the third quarter exceeded 13 billion U.

Merck:

Merck’s third-quarter revenue growth was strong, with a year-on-year increase of 19%
.

In the third quarter of 2021, the revenue of the Human Health Division reached US$11.

Keytruda ($4.

When asked about the drug resistance and carcinogenicity of molnupiravir by an analyst from SVB Leerink, Dean Li, president of Merck R&D, emphasized the safety of the drug in human trials
.

He reiterated that people need to recognize that molnupiravir is a nucleoside analogue that works by making errors in the genetic material of RNA viruses

Roche:

Roche:

Roche's revenue in the first three quarters of 2021 increased by 8% year-on-year, but it is worth noting that its growth momentum comes entirely from Roche Diagnostics (+39%)
.

The revenue of the pharmaceutical sector is the same as in the first three quarters of 2020, and it is not expected that there will be significant growth in the next few quarters.

Wall Street investors are very concerned about whether Roche's gantenerumab has enough confidence that it will not repeat the mistakes of Biogen Aduhelm, whether it will apply for Accelerated Approval (Accelerated Approval), and pointedly pointed out that gantenerumab does not have data to improve patient cognition
.
The company's management believes that gantenerumab has two characteristics that distinguish it from other competitors
.
One is that if the company submits an application for formal approval to the FDA in the second half of 2022, there will be 27 months of human test data for the gantenerumab phase III trial.
The long-term test data will be useful for improving the progressive disease of Alzheimer's disease.
There is very important persuasiveness; the second is that gantenerumab will be administered by subcutaneous fat injection, which is much more convenient than other approved or researched drugs for Alzheimer's disease
.

In the first three quarters of 2021, Roche has 14 pipeline drugs in clinical phase III, of which 3 are for cancer and blood disease treatment, 3 are for neuroscience, and the other pipeline drugs are located in immunotherapy, infectious diseases and ophthalmology
.
If these potential drugs are successfully marketed, it may turn things around for Roche
.

0 2 companies TOP3 leading products of varying prospects for  Merck's Gardasil Sanofi Dupixent eye-catching performance

0 2 companies TOP3 leading products of varying prospects for  Merck's Gardasil Sanofi Dupixent eye-catching performance

On the answer sheets submitted by the multinational pharmaceutical companies in the third quarter, the performance of each TOP3 competitive product was different
.
Among them, the most eye-catching and promising ones are Merck's Gardasil and Sanofi Dupixent in the first echelon.
The sales of these two products in the third quarter exceeded 15 billion U.
S.
dollars, and reached a growth rate of more than 50%
.

When asked by analysts from JP Morgan Chase whether there is still strong demand for Gardasil and how the company predicts the long-term performance of this vaccine, Merck’s management believes that only 9% of the global population suitable for HPV vaccination have completed the vaccination.

.
If you consider the markets in China, Japan, and even other age groups in Europe and the United States, Gardasil will have an important opportunity for continued growth
.
Gardasil's growth will be slightly moderate in 2022, but Merck will introduce two new mass production facilities in 2023.
This is based on the optimistic outlook for Gardasil's long-term growth, which will become the company's main growth driver in the future
.

Dupixent has always been favored by the industry and has become the biggest driving force for Sanofi's global business growth
.
Due to market leadership in atopic dermatitis and indications for asthma and chronic sinusitis with nasal polyps, Dupixent's sales are growing steadily
.
In fact, in the past two years, Dupixent's quarterly sales have almost tripled.
Wall Street investors predict that its annual peak sales are likely to reach and exceed 10 billion euros, becoming one of the tens of billions of drugs
.

The same promising prospects in the analysis of TOP3 major products are drugs like AbbVie Skrizi, Novartis Cosentyx and Enbresto, Johnson & Johnson Stelara and Darzalex, and BMS's Revlimid
.
These drugs either exceed $1 billion in quarterly sales while maintaining a growth rate of 10%-30%, or quarterly sales exceed $2 billion but still have strong growth
.

The leading products in this list also include some mature drugs, such as Lantus and Enbrel
.
They can still bring huge revenue to the company, but they are already in the late stage of the product cycle, with a negative growth rate, and begin to silently provide the company with much-needed cash flow for the development and marketization of other new products
.

One worth mentioning on the list is Merck’s Keytruda
.
The quarterly sales have reached 4.
5 billion US dollars, but still maintained a growth rate of more than 20%
.
The profit that K medicine brings to Merck is huge, but at the same time, Merck also wants to break its dependence on K medicine and seek new growth points.
After all, K medicine will expire in 2028
.

source:

source:

1.
Major multinational pharmaceutical companies' financial reports for the third quarter of 2021

1.
Major multinational pharmaceutical companies' financial reports for the third quarter of 2021

2.
Major multinational pharmaceutical companies' third quarter 2021 earnings conference call

2.
Major multinational pharmaceutical companies' third quarter 2021 earnings conference call